| Jose M Moran, NP | |
|
1252 Wyoming St, Boulder City, NV 89005-2825 | |
| (702) 293-4488 | |
| Not Available |
| Full Name | Jose M Moran |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 2 Years |
| Location | 1252 Wyoming St, Boulder City, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679215503 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 852800 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yang Medical Services Pllc | 7315275773 | 26 |
News Archive
Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Nikki Willett, vice president of Marketing & Regulatory Affairs for Pilgrim, will address an audience of medical technology innovators at the ODT Conference & Exhibition 2009, October 7, in Fort Wayne, Indiana.
Scientists are learning that a lesser-studied region on the pandemic coronavirus is recognized by COVID-19 infection-fighting antibodies. These antibodies were identified in blood samples from previously infected patients, and were found to potently prevent the virus from infecting cells.
Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential "anti-tumor" drugs coated by nanocapsules.
Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
› Verified 6 days ago
| Entity Name | Yang Medical Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538729322 PECOS PAC ID: 7315275773 Enrollment ID: O20190822002079 |
News Archive
Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Nikki Willett, vice president of Marketing & Regulatory Affairs for Pilgrim, will address an audience of medical technology innovators at the ODT Conference & Exhibition 2009, October 7, in Fort Wayne, Indiana.
Scientists are learning that a lesser-studied region on the pandemic coronavirus is recognized by COVID-19 infection-fighting antibodies. These antibodies were identified in blood samples from previously infected patients, and were found to potently prevent the virus from infecting cells.
Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential "anti-tumor" drugs coated by nanocapsules.
Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
› Verified 6 days ago
| Entity Name | Healthnomic Partners Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740850106 PECOS PAC ID: 7315342094 Enrollment ID: O20210818001437 |
News Archive
Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Nikki Willett, vice president of Marketing & Regulatory Affairs for Pilgrim, will address an audience of medical technology innovators at the ODT Conference & Exhibition 2009, October 7, in Fort Wayne, Indiana.
Scientists are learning that a lesser-studied region on the pandemic coronavirus is recognized by COVID-19 infection-fighting antibodies. These antibodies were identified in blood samples from previously infected patients, and were found to potently prevent the virus from infecting cells.
Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential "anti-tumor" drugs coated by nanocapsules.
Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jose M Moran, NP 8379 W Sunset Rd Ste 210, Las Vegas, NV 89113-2243 Ph: (725) 200-3232 | Jose M Moran, NP 1252 Wyoming St, Boulder City, NV 89005-2825 Ph: (702) 293-4488 |
News Archive
Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, today announced that Nikki Willett, vice president of Marketing & Regulatory Affairs for Pilgrim, will address an audience of medical technology innovators at the ODT Conference & Exhibition 2009, October 7, in Fort Wayne, Indiana.
Scientists are learning that a lesser-studied region on the pandemic coronavirus is recognized by COVID-19 infection-fighting antibodies. These antibodies were identified in blood samples from previously infected patients, and were found to potently prevent the virus from infecting cells.
Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential "anti-tumor" drugs coated by nanocapsules.
Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
› Verified 6 days ago
Angelique J. Cross, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 999 Adams Blvd Ste 104-105, Boulder City, NV 89005 Phone: 702-698-8342 | |
Felicia Nicole Tracy, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 668 Otono Dr, Boulder City, NV 89005 Phone: 951-401-7481 | |
Maureen Blomquist, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 999 Adams Blvd Ste 104-105, Boulder City, NV 89005 Phone: 702-698-8342 Fax: 702-293-2807 | |
Casey Elizabeth Bunker, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 895 Adams Blvd, Boulder City, NV 89005 Phone: 702-293-0406 Fax: 702-293-0192 | |
Allison Palmer, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 901 Adams Blvd, Boulder City, NV 89005 Phone: 801-815-1451 | |
Melissa Hart, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 901 Adams Blvd, Boulder City, NV 89005 Phone: 702-698-8342 |